Eugen Leo serves as Chief Medical Officer at CatalYm. Prior, he served as CMO for Rigontec, where he helped facilitate the company’s acquisition by MSD (known as Merck & Co. in North America). Eugen brings more than 20 years of experience in industrial phase I-III development of targeted molecules in the immuno-oncology space, ranging from kinase inhibitors, antibodies and antibody derivatives to vaccines, antisense molecules and cell therapies. His contributions were instrumental in reaching proof-of-concept for the BiTE (bi-specific T-cell engager) antibody platform, ultimately leading to Micromet’s acquisition by Amgen in 2012, as well as for the development of various other first-in-class molecules in the immuno-oncology space. Previously, he served in various positions with increasing levels of responsibility in both biotech (e.g. Micromet, Oxford Biotherapeutics, Ambit Biosciences, Isarna Therapeutics) and large pharmaceutical companies (Johnson & Johnson, Merck-Serono). Eugen is a board-certified Hematologist and Medical Oncologist and holds an Associate Professorship at the University of Heidelberg. He studied medicine at the Universities of Freiburg, Cincinnati and Münster and obtained an MBA from Colorado State University.